Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBT Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBT Margin for 4 consecutive years, with 349.08% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 26406.0% to 349.08% in Q3 2025 year-over-year; TTM through Sep 2025 was 216.89%, a 12688.0% decrease, with the full-year FY2024 number at 96.43%, up 21614.0% from a year prior.
  • EBT Margin was 349.08% for Q3 2025 at bioAffinity Technologies, down from 317.59% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 22.05% in Q2 2022 to a low of 427752.87% in Q3 2022.
  • A 4-year average of 48222.85% and a median of 230.33% in 2025 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 42698613bps in 2023; the steepest drop was -881517bps in 2023.
  • bioAffinity Technologies' EBT Margin stood at 71380.35% in 2022, then soared by 100bps to 107.12% in 2023, then dropped by -25bps to 134.4% in 2024, then tumbled by -160bps to 349.08% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's EBT Margin are 349.08% (Q3 2025), 317.59% (Q2 2025), and 143.06% (Q1 2025).